Physician profile
David Bronaugh
NPI 1447358254
$8,136.11
in general payments reported to CMS, 2019-2025
51 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,919 · 2022: $1,248 · 2023: $1,553 · 2024: $1,785 · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,969.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,270.93 | 2021-2025 | |
| Amgen INC. | $846.23 | 2021-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $547.20 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $433.24 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $417.50 | 2021-2025 | |
| Pfizer INC. | $345.36 | 2021-2025 | |
| Lilly USA, LLC | $333.69 | 2021-2025 | Mounjaro, Amyvid, Jardiance |
| Sumitomo Pharma America, INC. | $327.09 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $302.53 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $301.43 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.71 | 2021-2024 | Jardiance |
| Dexcom, INC. | $196.75 | 2021-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $182.39 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $172.34 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.27 | 2021-2025 | Xifaxan, Trulance |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $135.04 | 2021-2023 | Nexletol |
| Inspire Medical Systems, INC. | $129.05 | 2023-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $126.26 | 2021-2022 | |
| Novo Nordisk INC | $120.85 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Nevro Corp. | $107.69 | 2021-2024 | Senza |
| Horizon Therapeutics Plc | $97.28 | 2023 | Krystexxa |
| Teva Pharmaceuticals USA, INC. | $90.10 | 2021-2025 | Austedo, Austedo Xr |
| Amarin Pharma, INC. | $89.71 | 2021-2022 | |
| Mylan Specialty L.P. | $89.08 | 2021-2024 | Yupelri |
| Baxter Healthcare | $77.37 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Biogen, INC. | $75.97 | 2021-2022 | |
| Shield Therapeutics INC | $75.43 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $71.50 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $70.38 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.09 | 2022 | |
| Corcept Therapeutics | $60.40 | 2024-2025 | Korlym |
| Abbott Laboratories | $52.21 | 2021-2024 | Freestyle Libre 3 |
| Heartflow, INC. | $51.73 | 2022-2023 | Ffrct |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.73 | 2024-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $50.62 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.13 | 2022 | |
| Amneal Pharmaceuticals LLC | $43.42 | 2023 | Unithroid |
| Merck Sharp & Dohme LLC | $42.71 | 2022-2025 | Capvaxive, Gardasil 9 |
| Actelion Pharmaceuticals US, INC. | $36.61 | 2024-2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $33.18 | 2023-2025 | Watchman Access System |
| Sunovion Pharmaceuticals INC. | $30.16 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $29.90 | 2021-2022 | |
| Radius Health, INC. | $29.26 | 2021 | |
| Neurocrine Biosciences, INC. | $25.95 | 2025 | |
| Biotronik Nro, INC. | $23.57 | 2025 | Prospera |
| Sanofi Pasteur INC. | $20.14 | 2025 | |
| Kyowa Kirin, INC. | $16.77 | 2024 | Crysvita |
| C2n Diagnostics, LLC | $14.14 | 2025 | Precivityad2 |
| Tonix Medicines, INC. | $14.05 | 2025 | Tonmya |
| Linus Health, INC. | $13.99 | 2023 | |
| Theracosbio, LLC | $11.98 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bronaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.